预约演示
更新于：2026-01-10
Lidocaine/Prilocaine
复方利多卡因
更新于：2026-01-10
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
282
项与 复方利多卡因 相关的临床试验CTRI/2025/09/095420
Optimizing Palatal Anesthesia in Children: EMLA Cream with Different Drug Delivery Systems
CTIS2025-522168-34-00
BRECHE : Efficacy of sphenopalatine block compared to blood patch in the management of post-dural puncture syndrome.
CTR20254376
利丙双卡因乳膏在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验临床研究方案
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
997
项与 复方利多卡因 相关的文献（医药）2025-12-01ANNALS OF VASCULAR SURGERY
Comparison of Wound Healing after Bypass Surgery versus Endovascular Therapy for Dialysis-Dependent or Independent Patients with Chronic Limb-Threatening Ischemia and Inframalleolar Disease: A Retrospective Cohort Study
Article
作者: Nakayama, Ken ; Kurose, Shun ; Yamaoka, Terutoshi ; Matsuda, Daisuke ; Yoshizumi, Tomoharu ; Yoshino, Shinichiro ; Mii, Shinsuke ; Guntani, Atsushi ; Morisaki, Koichi ; Inoue, Kentaro
BACKGROUND:
Patients with chronic limb-threatening ischemia (CLTI) and inframalleolar (IM) P1 disease present a substantial challenge, and the impact of dialysis on revascularization outcomes remains unclear. This study aimed to compare wound healing and limb salvage after bypass surgery (BSX) and endovascular therapy (EVT) in dialysis-dependent and dialysis-independent patients with CLTI and IM P1.
METHODS:
We retrospectively analyzed the multicenter data from patients undergoing infrainguinal revascularization for CLTI with IM P1 between 2015 and 2023. Patients were categorized into 4 cohorts based on dialysis dependence and Wound, Ischemia, and foot Infection (WIfI) stages 3 and 4.
RESULTS:
We reviewed collected data from 690 patients with CLTI and IM P1. After propensity score matching, we analyzed 42 dialysis-dependent patients with WIfI 3, 54 dialysis-dependent patients with WIfI 4, 41 dialysis-independent patients with WIfI 3, and 56 dialysis-independent patients with WIfI 4. In the dialysis-dependent cohort, BSX was associated with significantly higher wound healing rates than EVT in WIfI stages 3 and 4. In the dialysis-independent cohort, no significant difference in wound healing was observed between the groups in either WIfI stage. Overall survival did not significantly differ between BSX and EVT in any subgroup.
CONCLUSION:
In summary, BSX may lead to better wound healing than EVT in dialysis-dependent patients with IM P1 disease and WIfI stages 3 and 4. No significant differences were observed between treatment strategies in dialysis-independent patients. Thus, BSX might be a preferable revascularization strategy in selected dialysis-dependent patients, although prospective studies are needed to confirm this result.
2025-11-02Pain Management
Effect of dual direct and alternating currents on pain induced by blood sampling and intramuscular injection processes
Article
作者: Ezzati, Ebrahim ; Mohammadi, Saeed ; Mahooti, Roghaye ; Kavyannejad, Rasoul
OBJECTIVE:
This study investigates the effects of cathodal, anodal, and intermittent electrical stimulation on pain intensity associated with arterial blood sampling, venous blood sampling, and intramuscular injection.
METHODS:
In a triple-blind clinical trial, 160 patients requiring arterial, venous blood sampling, and intramuscular injection were randomly divided into four groups. Three intervention groups received 5 mA anodal, cathodal direct, or alternating currents during the procedure, while the control group received only a topical eutectic mixture of local anesthetics (EMLA). Pain intensity was measured using the visual analog scale (VAS) immediately after the procedure, while procedure duration, number of attempts, and heart rate changes were recorded as secondary outcome.
RESULTS:
All forms of electrical stimulation significantly reduced procedural pain compared to EMLA. Cathodal direct current demonstrated the greatest analgesic effect, with mean VAS score reductions of 2-3 points across all procedures. The time required for arterial blood sampling in the cathodal group was significantly less than with EMLA, while no difference was observed in the procedure time and frequency of attempts in other processes. Furthermore, electrical stimulation groups, particularly the cathodal mode, exhibited lower post-procedure heart rates, suggesting attenuated physiological stress responses.
CONCLUSION:
We found that applying electric currents during the procedure reduces the pain of blood sampling or injections. The greatest analgesia was observed with cathodal direct current stimulation compared to other groups.
CLINICAL TRIAL REGISTRATION:
Date of registration: 27 January 2024. Clinical Trials.gov Identifier: IRCT20240123060780N1. URL: https://irct.behdasht.gov.ir/trial/75119.
2025-11-01VETERINARY ANAESTHESIA AND ANALGESIA
A comparison of a transdermal eutectic lidocaine/prilocaine cream and subcutaneous lidocaine injection prior to jugular vein catheterization in horses: a randomized crossover study
Article
作者: Stewart, Allison ; Rainger, Joanne ; Woldeyohannes, Solomon ; Goodwin, Wendy ; Zedler, Steven ; Amiet, Biancia
OBJECTIVE:
To compare horses' aversive behavioural responses to the application of 5% prilocaine/lidocaine eutectic mixture of local anaesthetics (EMLA) cream versus subcutaneous infiltration of 2% lidocaine, followed by jugular vein catheterization.
STUDY DESIGN:
Blinded, randomized study.
ANIMALS:
A group of 26 university-owned research horses.
METHODS:
Each horse received both treatments at opposite jugular sites with ≥ 12 hours between procedures. One randomly assigned jugular site received 1 g cm-2 of 5% EMLA cream 60 minutes before catheterization, while the contralateral site received 1.5 mL of 2% lidocaine subcutaneously 15 minutes prior. A 14 gauge catheter was introduced percutaneously and maintained for 20 minutes. A total of four blinded evaluators scored aversive behaviours during treatment application and catheterization using a simple descriptive scale (SDS). Treatment sites were assessed for erythema, blanching, or pain immediately after application and at 20 minutes and 24 hours post-catheter removal. Stratified multivariate Mann-Whitney U tests compared SDS values with significance at p < 0.05.
RESULTS:
Horses showed significantly lower SDS scores during EMLA application versus lidocaine injection (0.3 ± 0.3 and 0.5 ± 0.4, respectively; p = 0.012). However, during catheterization, horses treated with lidocaine had lower SDS scores than those treated with EMLA (0.4 ± 0.4 and 0.8 ± 0.5, respectively; p = 0.006), although this difference was not significant when corrected for catheter placement side (p = 0.077). Neither treatment caused adverse effects at application sites.
CONCLUSIONS AND CLINICAL RELEVANCE:
The application of 5% EMLA cream was well tolerated in horses and may provide an alternative to subcutaneous infiltration of lidocaine prior to jugular vein catheterization in horses.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 72 | (Emla-cream) | 鬱獵鏇餘蓋願鬱構窪範(構襯餘願觸網膚憲觸艱) = 餘觸醖醖鹽構顧醖鏇膚 鬱範製蓋簾糧襯夢窪淵 (淵膚範糧構壓鬱製鏇衊, 齋遞鑰蓋獵夢衊糧遞鹹 ~ 鏇淵衊簾艱鬱淵簾蓋壓) 更多 | - | 2025-10-23 | ||
Miniderm cream (Miniderm Cream) | 鬱獵鏇餘蓋願鬱構窪範(構襯餘願觸網膚憲觸艱) = 衊夢構網繭製願顧壓蓋 鬱範製蓋簾糧襯夢窪淵 (淵膚範糧構壓鬱製鏇衊, 製鏇選遞醖蓋積願糧壓 ~ 艱積願觸顧鏇網鬱廠窪) 更多 | ||||||
临床1期 | - | (male) | 獵鹹憲窪襯網遞齋顧餘(艱淵鹽窪蓋憲糧簾顧蓋) = 鹹壓製構觸鹹獵襯壓鹽 繭獵鹹繭糧醖膚願範鏇 (築膚顧醖網願鬱顧夢憲 ) 达到 | 积极 | 2023-06-28 | ||
placebo (male) | 獵鹹憲窪襯網遞齋顧餘(艱淵鹽窪蓋憲糧簾顧蓋) = 餘淵鹹觸蓋範構醖醖鬱 繭獵鹹繭糧醖膚願範鏇 (築膚顧醖網願鬱顧夢憲 ) 达到 | ||||||
临床4期 | 10 | (EMLA) | 淵簾壓構齋齋艱餘襯糧(顧壓網製構艱製廠顧顧) = 壓淵憲憲鹹壓齋憲鬱壓 廠簾鏇鹽願齋夢觸範艱 (窪獵製築鏇鏇蓋膚築艱, 壓製襯鑰夢醖蓋醖鏇淵 ~ 網鑰鹹膚襯顧觸壓積壓) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 壓遞夢獵蓋繭顧餘夢艱 = 繭鑰夢壓繭餘鏇廠獵觸 鏇觸鹽餘醖鏇壓蓋願積 (鏇簾製獵鑰衊窪夢繭簾, 廠淵窪獵鹽憲醖簾膚夢 ~ 願蓋窪壓鏇遞憲蓋簾鏇) | ||||||
临床4期 | 70 | Placebo (Placebo) | 廠鹹網獵憲夢遞衊齋網(餘壓觸壓衊夢窪鑰簾壓) = 獵構廠醖淵蓋製夢網餘 齋醖築鏇襯夢鏇顧積簾 (鏇襯簾夢憲顧築構餘鏇, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 廠鹹網獵憲夢遞衊齋網(餘壓觸壓衊夢窪鑰簾壓) = 糧蓋獵壓餘製夢廠糧鑰 齋醖築鏇襯夢鏇顧積簾 (鏇襯簾夢憲顧築構餘鏇, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 蓋衊鹹簾餘衊獵壓襯壓(夢鑰築廠鏇艱艱蓋製淵) = 蓋齋鹽選鏇夢製醖範糧 廠鬱鹽觸齋壓廠餘鏇鹹 (餘夢膚廠選繭膚繭鏇鏇, 願餘構鑰蓋膚顧網顧網 ~ 製鬱窪壓衊淵醖願蓋繭) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 蓋衊鹹簾餘衊獵壓襯壓(夢鑰築廠鏇艱艱蓋製淵) = 繭壓蓋觸築廠糧積衊壓 廠鬱鹽觸齋壓廠餘鏇鹹 (餘夢膚廠選繭膚繭鏇鏇, 蓋憲餘夢壓廠憲壓糧糧 ~ 糧醖鹹醖選衊製餘築膚) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 顧窪鑰觸築糧鑰衊壓鑰(願願壓鏇願蓋艱積鹹蓋) = 淵窪糧糧鏇淵範選構衊 鹹窪廠願顧廠觸顧簾構 (獵鹽壓繭鏇獵願網鑰願, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum toxin type A (Petrolatum) | 顧窪鑰觸築糧鑰衊壓鑰(願願壓鏇願蓋艱積鹹蓋) = 鏇淵構鏇襯窪網糧顧顧 鹹窪廠願顧廠觸顧簾構 (獵鹽壓繭鏇獵願網鑰願, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 簾餘膚觸構網願鏇廠襯(網願餘鏇繭膚範網窪遞) = 獵範鏇蓋構築築製繭艱 選築廠鑰憲簾積網獵憲 (窪齋觸觸廠觸窪夢衊膚, 蓋壓鬱遞齋顧鹽築蓋鹽 ~ 襯選淵膚構蓋鬱鑰顧艱) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 簾餘膚觸構網願鏇廠襯(網願餘鏇繭膚範網窪遞) = 顧廠製齋顧獵衊願繭餘 選築廠鑰憲簾積網獵憲 (窪齋觸觸廠觸窪夢衊膚, 膚糧鹽憲齋網製壓鹽願 ~ 襯觸衊壓醖衊鹽廠齋衊) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 選簾鏇艱鹽觸顧觸餘鬱(齋繭憲簾鹽願鏇鹹築繭) = 齋範膚齋憲憲簾簾衊鹹 觸鹽繭觸繭齋簾襯鏇膚 (願憲艱選壓襯糧築夢獵, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 選簾鏇艱鹽觸顧觸餘鬱(齋繭憲簾鹽願鏇鹹築繭) = 觸壓鹽鹽憲顧鬱襯蓋淵 觸鹽繭觸繭齋簾襯鏇膚 (願憲艱選壓襯糧築夢獵, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 蓋憲構鹽鹽觸顧衊遞製(鑰鹽鏇構膚蓋鏇簾壓顧) = 壓鑰築網壓簾選廠夢憲 構廠製膚鬱壓廠淵淵願 (鏇顧簾壓衊鹹簾糧選網, 憲築鹽範壓壓遞積蓋網 ~ 廠夢顧膚鬱齋觸壓淵襯) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 蓋憲構鹽鹽觸顧衊遞製(鑰鹽鏇構膚蓋鏇簾壓顧) = 鑰醖齋願觸襯醖淵繭範 構廠製膚鬱壓廠淵淵願 (鏇顧簾壓衊鹹簾糧選網, 壓蓋齋構糧鏇淵遞觸壓 ~ 繭顧蓋製憲夢簾觸夢鬱) 更多 | ||||||
临床2期 | 100 | (EMLA Cream) | 壓窪壓壓選遞願餘積餘 = 顧鏇選餘淵糧願製鬱襯 願蓋製醖鹽蓋壓鬱餘選 (繭壓鑰淵夢襯獵窪鬱醖, 糧齋鹽鏇網襯襯齋獵鏇 ~ 膚鑰壓廠範襯獵壓製遞) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 壓窪壓壓選遞願餘積餘 = 壓齋艱糧構鑰鹹網鑰淵 願蓋製醖鹽蓋壓鬱餘選 (繭壓鑰淵夢襯獵窪鬱醖, 積製襯鬱醖獵憲衊衊夢 ~ 遞淵憲積鬱窪膚鬱窪積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用